Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Finance News Network Investor Event (October 2018)
17 slides from Kazia Therapeutics's conference presentation, Oct 11, 2018
Slide 1: Cancer-focused biotech with two clinical-stage programs
Cancer-focused biotech with two clinical-stage programs Presentation to Finance News Network Investor Event Sydney, NSW 11 October 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Highlights
Investment Highlights 1 Cancer drug developer with two distinct therapies in clinical trials - GDC-0084 in phase II trial for brain cancer - Cantrixil in phase I trial for ovarian cancer 2 Lead program, GDC-0084, acquired from Genentech following their strategic deprioritisation and now in phase II
Slide 4: Kazia strategy to develop high-quality assets from external sources
Kazia strategy to develop high-quality assets from external sources Partner with big pharma for late-stage development to bring to market Bring in under-valued assets from other pharmaceutical companies Conduct focused clinical trials Identify optimal patient groups Understand safety and dosing Enga
Slide 5: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Chairman Executive and Board roles in pharma and small biotech Bryce Carmine Deputy Chairman 36 years executive experience in Eli Lilly Steven Coffey Non-Executive Director C
Slide 6: Two clinical programs, with value-driving inflection points during 2018-19
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018-19 GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Preliminary data from phase 1 study in ovarian cancer Data read-out from phase 1 study (safety and dosing) ü Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 7: Kazia is NASDAQ & ASX listed with ~$9.3M of current assets at 30 June 2018
Kazia is NASDAQ & ASX listed with ~$9.3M of current assets at 30 June 2018 Market Capitalisation (at 30 September 2018) AU$ 20.6 million Shares on Issue 48.3 million (35% US, 65% Australia) Current Assets AU$ 9.3 million Listing ASX: KZA NASDAQ: KZIA (1:10 ratio) Share Price (AU$) Outstanding Option
Slide 8: Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 9: Growing public attention for brain cancer highlights need for new treatment options
Growing public attention for brain cancer highlights need for new treatment options There is increasing recognition of the need to find treatment options for patients diagnosed with GBM Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new tr
Slide 10: Current standard of care is essentially ineffective in approximately 65% of GBM cases
Current standard of care is essentially ineffective in approximately 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Standard of Care (‘Stupp Regimen’) Debulking surgery where possible Radiotherapy + temozolomide Temozolomide maintenance therapy 6 w
Slide 11: The PI3K inhibitor class is well-validated, but GDC-0084 is the only brain-penetrant drug in GBM
The PI3K inhibitor class is well-validated, but GDC-0084 is the only brain-penetrant drug in GBM Two marketed products in the PI3K class validate this approach to treating cancer GDC-0084 is essentially unique in being able to cross the blood-brain barrier Two PI3K inhibitors now successfully brough
Slide 12: Phase I of GDC-0084 established dosing and showed favourable safety
Phase I of GDC-0084 established dosing and showed favourable safety * Taal et al., Lancet Oncology (2015): ORR and mPFS of Lomustine in 2L GBM were 2/41 (5%) and 1 months, respectively (n = 46) † Schwarzenberg J, et al. Clin Cancer Res; 20(13); 3550–9 Efficacy Signals Safety Phase I safety trial con
Slide 13: In GDC-0084 phase I, 26% of patients showed a metabolic partial response on FDG-PET
In GDC-0084 phase I, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084
Slide 14: Multipart GDC-0084 phase II design allows for frequent data read-outs
Multipart GDC-0084 phase II design allows for frequent data read-outs to inform partnering and early approval Note: timelines are estimated, and subject to periodic revision based on recruitment performance and treatment effect Step 1 Dose Optimisation Step 2 Expansion Cohort Step 3 Planned Registra
Slide 15: Recent collaboration with St Jude expands GDC-0084 into childhood brain cancer
Recent collaboration with St Jude, a leading US paediatric hospital, expands GDC-0084 into childhood brain cancer Preclinical Phase I Phase II Phase III GDC-0084 PI3K / mTOR Inhibitor Licensed from Genentech in October 2016 Glioblastoma Multiforme (GBM) (Kazia-sponsored) Ovarian Cancer (Kazia-sponso
Slide 16: Investment Highlights
Investment Highlights 1 Cancer drug developer with two distinct therapies in clinical trials - GDC-0084 in phase II trial for brain cancer - Cantrixil in phase I trial for ovarian cancer 2 Lead program, GDC-0084, acquired from Genentech following their strategic deprioritisation and now in phase II
Slide 17: Kazia Therapeutics
-KAZIA THERAPEUTICS www.kaziatherapeutics.com info@kaziatherapeutics.com
Kazia Therapeutics — Finance News Network Investor Event (October 2018) on 6ix